Kutatási jelek – Signal Engine

• Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia — Melanoma
• Englumafusp alfa plus glofitamab in B cell non‑Hodgkin lymphoma: a phase 1 trial — Lymphoma
• North American Enrollment in Clinical Trials: An Emerging Issue for Regulatory Approval — NSCLC
• A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer — Colorectal cancer
• Ras‑MAPK inhibition induces AXIN1 loss in colorectal cancer by mTOR associated suppression of protein synthesis — Colorectal cancer
• Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response — Colorectal cancer
• A PML1-CCL5-PI3K/MAPK feedback loop governs survival of endocrine-resistant breast cancer cells — Breast cancer
• Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis — SCLC
• EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy — SCLC
• Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial — Colorectal cancer
• Emergence of Sprouty role from the signaling interplay of DUSP1 and DUSP4 interactions in NSCLC pathogenesis — NSCLC
• Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials — NSCLC
• Overcoming immune evasion: a new combination therapy advances treatment for a rare metastatic eye cancer — Melanoma
• Improvements in Real‑World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment — Acute myeloid leukemia
• Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) — Ewing sarcoma
• Atlantic Health Treats First Patient in Northeast for Glioblastoma with New Cellular Immunotherapy in Phase 2 Clinical Trial — Glioblastoma
• Phase 3 Trial of Optune, Temozolomide, and Pembrolizumab in Newly Diagnosed Glioblastoma — Glioblastoma
• Significant New Treatment Options Emerge for Patients With CLL — Chronic lymphocytic leukemia
• FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC — Hepatocellular carcinoma
• A trial of SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma (The Scope Study) — Melanoma